Fernando Andreu

CEO

Fernando Andreu (B. 1964) is CEO of 2cureX AB and 2cureX A/S since 2021.

Fernando brings to the company more than 30 years’ experience in the In Vitro Diagnostics industry, having held top management positions at companies like Chiron, Roche Diagnostics and Sysmex, always with a focus in Global Business Development. Most recent positions include CEO at Sysmex Inostics (affiliate of Sysmex developing Liquid Biopsy technologies and products in oncology), Senior Executive Officer at Sysmex EMEA, COO of Indivumed Group (multi-omics database and AI platform for cancer discovery) and CEO of Indivumed Inc (US affiliate of Indivumed).

He holds a Degree in Business Administration and an MBA from ESADE Business School (Barcelona) where he has also been a Professor, associated to the Business Strategy Department.

2cureX share ownership and warrants
14 741 shares

Ole Thastrup

CSO and Deputy CEO

Ole Thastrup (B. 1953) is CSO and Deputy-CEO of 2cureX AB and 2cureX A/S.

Ole Thastrup (B. 1953) is co-founder of 2cureX. He has been a board member of 2cureX since its inception.

Ole holds an MSc in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also a Professor at the University of Copenhagen. Prior to 2cureX, Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg’s biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now part of Thermo Fisher Scientific) which was spun out from Novo Nordisk A/S. Ole is the inventor in several families of globally issued patents. He had advised several venture capital funds and is a member of granting institutions (e.g. Novo Nordisk Foundation).

2cureX share ownership and warrants
3 778 304 shares via own company

Other board assignments OT311 APS

Independence Affiliated to management, the company, and major shareholders

Kenneth Graabek Johansen

Chief Financial Officer

Kenneth Graabek Johansen (B.1976) is CFO of 2cureX AB and 2cureX A/S since 2021.

With more than 15 years of experience in business development and financial administration from the intersection of the biomedical area and advanced data analysis, Kenneth is fully engaged in delivering excellent business operations. More recent and relevant experience includes COO of JADBio (Greece), CEO of Raven biosciences (DK), CEO of QIAGEN Aarhus (DK) and CFO of CLC bio (DK).

In addition, he has several years working in audit with KPMG (DK), and holds a BA in Financial Management and Accounting.

2cureX share ownership and warrants
4 000 shares

Grith Hagel

Chief Operating Officer

Grith holds a degree of Biomedical Laboratory Science.

Grith has comprehensive experience in developing and running drug screening campaigns. Grith is the inventor in several patents on advanced cell-based, high throughput screening technologies. She is a co-founder of BioImage A/S, spun out of Novo Nordisk and now part of the imaging division of Thermo Fisher Scientific. She was responsible for the development of functional cell-based assays, and for their transfer to partners such as Amersham plc (now GE Healthcare).

2cureX share ownership and warrants
681 708 shares

Jürgen Kupper

Vice-President of Strategic Alliances

Jürgen Kupper (B. 1965) joined 2cureX in 2015.

He began his career at Evotec AG in 1999. Jürgen’s previous positions include COO of Evotec Technologies, Product Leader for Live Cell Imaging at PerkinElmer and Managing Director of the Diagnostic Center at the University Medical Center Hamburg-Eppendorf (UKE). Jürgen holds a PhD in Biophysics from Brandeis University, USA.

2cureX share ownership and warrants
43 400 shares

Jesper Floyd Kristiansen

VP Global Business Development

Jesper Floyd Kristiansen (B. 1965) joined 2cureX in August 2021 as VP Business Development Europe.

Jesper brings in years of work experience and knowledge in cancer diagnostic and international contact network within pathology and oncology.

Jesper has since year 2000 worked in the In Vitro Diagnostic field. He established Dako (now Agilent) in Poland and ran their cancer diagnostic activities there for 12 years. Beside Poland he was also involved in supporting the distributor business in East Europe and Africa. Then 2 years in Infectious area as VP Sales & Marketing at ArcDia International in Finland, where he among other expanded the distributor network. From 2014 Jesper was Export Director and responsible for setting up the global distributor network and developing the distributor sales in molecular diagnostic testing at Biocartis NV in Belgium. Jesper has a Degree from the Danish Commercial College.

2cureX share ownership and warrants
8 354 shares

Mark C. Gray

Director of Communications

Mark C. Gray (b. 1970) joined 2cureX as Director of Communications on 1 March 2022.

Mark is an experienced communications specialist with extensive background in the IVD sector and as an independent writer.

Mark was Assistant Director of Marketing Communications at Sysmex Europe GmbH, where he was responsible for all English-language communications for the 23 distributors in the EMEA region as well as the corporate communications. In addition, he was responsible for developing the company’s corporate and employer brands.

In addition to his work at 2cureX, Mark continues his work as independent writer and branding specialist, with a specific focus on true-to-brand communications.

2cureX share ownership and warrants
0 shares

Manuel Fernández

Quality & Regulatory Director

Manuel Fernández joined 2cureX in 2022.

Manuel Fernández has nearly 30 years’ experience in Diagnostics and Medical Devices. His academic background is in mechatronics, robotics and automation engineering, as well as biomedical engineering Bachelor’s Degree. He also completed Masters Degree in Clinical Engineering and Radiation Physics.

Throughout his career he has led the QA / RA function in several companies, becoming an expert in all relevant ISO norms. He has deep knowledge of the regulatory landscapes in Europe, US, China and Asia Pacific, and has been part of Notified Bodies, (BSI), as well working with competent regulatory authorities in major countries. He is a certified FDA-MDSAP Auditor, certified ISO 13485, ISO 27001 and ISO9001 Lead Auditor, certified FDA-Clinical Investigator Inspector and certified FDA Pharmaceutical QMS Auditor, among others.

2cureX share ownership and warrants
0 shares

Raphael Gruber

Medical Director

Raphael Gruber (b. 1964) joined 2cureX in 2022.

Raphael previously held the position of Medical Director at Exact Sciences for the DACH/NL region, where he successfully led the company´s medical strategies to introduce their multigene IVD assay into national reimbursement in Germany and the Netherlands. He spent ten years at Otsuka Pharmaceuticals Europe where he headed the EU Medical Devices division. Raphael is a board-certified general surgeon and holds a PhD in pathology from Goethe University, Frankfurt, Germany.

2cureX share ownership and warrants
0 shares

Tabea Sturmheit

Director of Research

Tabea Sturmheit (b. 1985) joined 2cureX in 2017.

Tabea has a strong background in cancer biology & immunology, as well as stem cell biology. She has worked in several academic research labs across Europe (DE, IT, NL, CH). Prior to joining 2cureX, Tabea held a post-doc position at a Fraunhofer Research Institution in Lübeck (Germany), developing in vitro test systems for wound healing applications.

Tabea joined the 2cureX research department in 2017 and has since been dedicated to expanding the company’s product pipeline. She is a guest scientist in the Center for Oncology at the University Center Hamburg-Eppendorf (UKE) and, since January 2022, a member of the 2cureX management team.

Tabea holds a PhD in cellular and molecular biology from San Raffaele University, Milan (Italy).

2cureX share ownership and warrants
0 shares

Jacop Thastrup

Director of Product Development

Jacob Thastrup (b. 1979) joined 2cureX in 2009.

Jacob joined 2cureX in 2009 as a Research Scientist after completing his PhD in Biochemistry from the University of Dundee, Scotland. Jacob has extensive knowledge of intra- and extra-cellular signaling and has worked in the field of cancer research since 2002. Jacob has more than a decade of experience developing in vitro diagnostic products for use in personalized medicine. As Director of Product Development Jacob is responsible for transitioning research prototypes into IVD-R certifiable products.

2cureX share ownership and warrants
10 919 shares